-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs.
The award is expected to commence in Q3 2024 and will support the planned expansion of the company's clinical trial for pediatric brain cancer.
"This recent award further extends our current cash runway in the second half of 2025 while supporting the 2024 expansion of our clinical development activities," said Marc Hedrick, President & CEO of Plus Therapeutics.
"In 2023, the company applied for approximately $7 million in grant funding, and we plan to file for more than $10 million in funding in 2024," Hedrick added.
The DoD Peer Reviewed Cancer Research Program (PRCRP) Advancing Cancer Care through Clinical Trials Award will be utilized to fund a Phase 1 dose escalation trial to address the FY23 PRCRP Topic Area of Pediatric Brain Tumors.
This study will investigate a novel therapeutic, Rhenium (186Re) Obisbemeda (186RNL), delivered by Convection Enhanced Delivery, for supratentorial recurrent, refractory, or progressive pediatric high-grade glioma and ependymoma.
Patient enrollment is expected to start in the second half of 2024.
Plus Therapeutics has $23 million in active awards support for the company's targeted radiotherapeutic pipeline.
Rhenium (186Re) obisbemeda is an injectable radiotherapy specifically formulated to deliver direct targeted high-dose radiation in central nervous system (CNS) tumors.
Rhenium (186Re) obisbemeda is being evaluated for recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials.
ReSPECT-GBM is supported by an award from the National Cancer Institute, part of the U.S. National Institutes of Health, and ReSPECT-LM is funded by a three-year $17.6 million grant by the Cancer Prevention & Research Institute of Texas.
Price Action: PSTV shares closed at $1.63 on Friday.
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs.
Plus Therapeutics Inc(納斯達克股票代碼:PSTV)已被國防部(國防部)國會指導的醫學研究計劃辦公室選中300萬美元的資助建議。
The award is expected to commence in Q3 2024 and will support the planned expansion of the company's clinical trial for pediatric brain cancer.
該獎項預計將於2024年第三季度開始,將支持該公司計劃擴大兒科腦癌臨床試驗。
"This recent award further extends our current cash runway in the second half of 2025 while supporting the 2024 expansion of our clinical development activities," said Marc Hedrick, President & CEO of Plus Therapeutics.
Plus Therapeutics總裁兼首席執行官馬克·赫德里克表示:“最近的這項獎項進一步延長了我們在2025年下半年目前的現金流道,同時支持我們在2024年擴大臨床開發活動。”
"In 2023, the company applied for approximately $7 million in grant funding, and we plan to file for more than $10 million in funding in 2024," Hedrick added.
赫德里克補充說:“2023年,該公司申請了約700萬美元的補助金,我們計劃在2024年申請超過1000萬美元的資金。”
The DoD Peer Reviewed Cancer Research Program (PRCRP) Advancing Cancer Care through Clinical Trials Award will be utilized to fund a Phase 1 dose escalation trial to address the FY23 PRCRP Topic Area of Pediatric Brain Tumors.
國防部同行評審癌症研究計劃(PRCRP)通過臨床試驗促進癌症護理獎將用於資助一項1期劑量遞增試驗,該試驗旨在解決23財年PRCRP小兒腦腫瘤主題領域。
This study will investigate a novel therapeutic, Rhenium (186Re) Obisbemeda (186RNL), delivered by Convection Enhanced Delivery, for supratentorial recurrent, refractory, or progressive pediatric high-grade glioma and ependymoma.
這項研究將研究一種由對流增強輸送提供的新型治療藥物瑞(186Re)Obisbemeda(186RNL),用於治療腸上覆發、難治性或進行性兒科高級神經膠質瘤和室管膜瘤。
Patient enrollment is expected to start in the second half of 2024.
患者入組預計將於2024年下半年開始。
Plus Therapeutics has $23 million in active awards support for the company's targeted radiotherapeutic pipeline.
此外,Therapeutics爲該公司的靶向放射治療產品線提供了2300萬美元的活躍獎勵支持。
Rhenium (186Re) obisbemeda is an injectable radiotherapy specifically formulated to deliver direct targeted high-dose radiation in central nervous system (CNS) tumors.
Rhenium (186Re) obisbemeda 是一種可注射的放射療法,專門爲中樞神經系統 (CNS) 腫瘤提供直接靶向高劑量輻射而配製。
Rhenium (186Re) obisbemeda is being evaluated for recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials.
在Respect-GBM和Respect-LM臨床試驗中,正在對Rhenium(186Re)obisbemeda進行復發性膠質母細胞瘤和輕腦膜轉移的評估。
ReSPECT-GBM is supported by an award from the National Cancer Institute, part of the U.S. National Institutes of Health, and ReSPECT-LM is funded by a three-year $17.6 million grant by the Cancer Prevention & Research Institute of Texas.
Respect-GBM由美國國立衛生研究院下屬的國家癌症研究所的獎勵支持,Respect-LM由德克薩斯州癌症預防與研究所爲期三年的1760萬美元撥款資助。
Price Action: PSTV shares closed at $1.63 on Friday.
價格走勢:PSTV股價週五收於1.63美元。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧